Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Martin Dreyling, Michael Kneba et al.|The Lancet|2016Cited by 401
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Martin Dreyling, Eva Hoster et al.|Blood|2009Cited by 269
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 casesAnastasia Hadzidimitriou, Κώστας Σταματόπουλος, Andreas Agathangelidis et al.|Blood|2011Cited by 178
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Wolfgang Hiddemann et al.|Blood|2015Cited by 157